文献速递脑血管病神经重症与神经感染

自发性脑出血患者限制性与开放性输血策略:TRAIN随机临床试验二次分析

A Restrictive Versus a Liberal Transfusion Strategy in Patients With Spontaneous Intracerebral Hemorrhage: A Secondary Analysis of TRAIN Randomized Clinical Trial.
PubMed 文献 · Stroke · 2025-06-17

该研究为TRAIN试验的二次分析,纳入144例自发性脑出血合并贫血的危重症患者,比较限制性(血红蛋白≤7 g/dL触发输血)与开放性(≤9 g/dL触发)策略对180天神经功能结局的影响。开放性组不良神经结局风险非显著降低(71.8% vs 84.7%,RR 0.85,95%CI 0.71-1.01,P=0.06),但28天死亡与器官衰竭复合结局显著降低(71.8% vs 87.7%,RR 0.82,95%CI 0.69-0.97,P=0.02)。

要点

  • 自发性脑出血贫血患者中,开放性输血策略未显著改善180天神经功能结局。
  • 开放性输血策略与28天死亡和器官衰竭复合结局风险显著降低相关。
  • 研究样本量可能不足以检测两组间临床相关差异。

核心结论

  • 在自发性脑出血患者中,与限制性输血策略相比,开放性输血策略与更低的死亡和器官衰竭风险相关,但未显著降低不良神经功能结局风险。

研究设计与样本

  • TRAIN随机临床试验的二次分析,原试验为前瞻性、多中心、3期随机研究,于2017至2022年在22个国家72个重症监护室开展。
  • 纳入标准为急性脑损伤、入院10天内血红蛋白≤9 g/dL、预期ICU停留至少72小时;本分析仅纳入自发性脑出血患者,共144例。
  • 患者随机接受限制性(血红蛋白≤7 g/dL触发输血)或开放性(血红蛋白≤9 g/dL触发输血)策略,持续28天。

主要发现

  • 144例患者中男性占45.8%,平均年龄58.4岁(SD 13.4),入院平均GCS 7.3(SD 3.3),75.7%患者血肿体积>30 mL。
  • 限制性组73例,开放性组71例,两组基线特征可比。
  • 180天不良神经结局(GOS-E评分1-5)发生率:开放性组71.8% vs 限制性组84.7%,RR 0.85(95%CI 0.71-1.01),P=0.06。
  • 28天死亡和器官衰竭复合结局发生率:开放性组71.8% vs 限制性组87.7%,RR 0.82(95%CI 0.69-0.97),P=0.02。

关键数值与推荐

  • 限制性输血策略触发阈值:血红蛋白≤7 g/dL。
  • 开放性输血策略触发阈值:血红蛋白≤9 g/dL。
  • 主要结局为随机后180天不良神经功能结局,定义为GOS-E评分1-5。

临床怎么用

  • 对于自发性脑出血合并贫血的危重症患者,开放性输血策略(血红蛋白≤9 g/dL触发)可能降低28天死亡和器官衰竭风险。
  • 但该策略未显著改善180天神经功能结局,临床决策需结合个体情况权衡。

局限性

  • 本研究为二次分析,样本量可能不足以检测两组间临床相关差异。
  • 研究仅纳入自发性脑出血患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Red blood cell transfusions are commonly administered to anemic patients with spontaneous intracerebral hemorrhage (ICH); however, the optimal hemoglobin threshold to initiate transfusion is uncertain in this population. Therefore, we aimed to assess the impact of 2 different hemoglobin thresholds to guide transfusion on the neurological outcome of anemic critically ill patients with ICH. METHODS: This is a secondary analysis of a prospective, multicenter, phase 3 randomized study conducted in 72 intensive care units across 22 countries from 2017 to 2022. Eligible patients for the original trial had an acute brain injury, hemoglobin values ≤9 g/dL within the first 10 days after admission, and an expected intensive care unit stay of at least 72 hours; in this study, only patients with spontaneous ICH were assessed. Patients were randomly assigned to undergo a restrictive (transfusion triggered by hemoglobin ≤7 g/dL) or a liberal (transfusion triggered by hemoglobin ≤9 g/dL) strategy over a 28-day period. The primary outcome was the occurrence of an unfavorable neurological outcome, defined as a Glasgow Outcome Scale Extended score of 1 to 5, at 180 days following randomization. RESULTS: A total of 144 patients with spontaneous ICH were analyzed: 45.8% of them were men with a mean age of 58.4 (SD, 13.4). Mean Glasgow Coma Scale on admission was 7.3 (SD, 3.3), and 75.7% of patients had a volume of hematoma >30 mL. Among all patients, 73 were randomized to the restrictive transfusion strategy, while 71 to the liberal one. Baseline characteristics were comparable between the 2 groups. At 180 days after randomization, patients assigned to the liberal transfusion strategy had a nonsignificant decrease in the probability of unfavorable neurological outcome (71.8 versus 84.7%; risk ratio, 0.85 [95% CI, 0.71-1.01]; P=0.06). Also, the occurrence of the composite outcome (mortality and organ failure at day 28) was significantly lower in the liberal group (71.8% versus 87.7%, risk ratio, 0.82 [95% CI, 0.69-0.97]; P=0.02). CONCLUSIONS: A liberal transfusion strategy was associated with a lower risk of mortality and organ failure, but not of unfavorable outcome in patients presenting with spontaneous ICH, compared with a restrictive strategy. However, the study cohort might have been underpowered to detect clinically relevant differences between the 2 interventions.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Faso C, Gouvea Bogossian E, Bittencourt Rynkowski C, et al. A Restrictive Versus a Liberal Transfusion Strategy in Patients With Spontaneous Intracerebral Hemorrhage: A Secondary Analysis of TRAIN Randomized Clinical Trial. Stroke. 2025. PMID: 40525290. doi:10.1161/STROKEAHA.125.050729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。